{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:29:16Z","timestamp":1787923756562,"version":"build-2784847793"},"reference-count":20,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Secondary hyperparathyroidism (SHPT) is a prevalent complication of end-stage kidney disease. Although etelcalcetide has demonstrated short-term superiority over cinacalcet in randomized trials, real-world comparative data beyond 12 months remain scarce. This study compared the long-term effectiveness of etelcalcetide versus cinacalcet in hemodialysis patients over 24 months using propensity score matching. Methods: This multicenter retrospective study screened 457 hemodialysis patients across five centers in T\u00fcrkiye. Propensity score matching on age, sex, hemodialysis vintage, and baseline intact parathyroid hormone (iPTH) yielded balanced cohorts of 21 versus 21 for 12-month and 14 versus 14 for 24-month analyses. The primary outcome was percentage change in iPTH from baseline (%\u0394PTH). Secondary outcomes included responder rates, KDIGO target achievement, response trajectory classification, and depth-of-response analysis. Results: At 12 months, etelcalcetide achieved significantly greater iPTH reduction (%\u0394PTH: \u221250.5 \u00b1 25.6% vs. \u221229.7 \u00b1 40.6%; p = 0.047), with effect sizes increasing from medium to medium\u2013large at 24 months (Cohen\u2019s d: \u22120.612 to \u22120.779). Sustained response (\u226530% iPTH reduction at both timepoints) was significantly higher with etelcalcetide (78.6% vs. 28.6%; p = 0.021), as was deep response (\u226575% reduction) at 24 months (57.1% vs. 14.3%; p = 0.046). At 24 months, etelcalcetide demonstrated significantly lower serum calcium (p = 0.015), calcium\u2013phosphate product (p = 0.023), and superior phosphate target attainment (85.7% vs. 28.6%; p = 0.004). Inter-patient response variability was nearly three-fold lower with etelcalcetide (CV: 42% vs. 151%). Conclusions: Etelcalcetide provided significantly greater, more sustained, and more consistent iPTH suppression than cinacalcet over 24 months, with additional benefits in mineral metabolism control. These findings support etelcalcetide as a potent therapeutic option for SHPT in hemodialysis patients and warrant confirmation in larger prospective trials.<\/jats:p>","DOI":"10.3390\/jcm15176656","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:27:46Z","timestamp":1787920066000},"page":"6656","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Etelcalcetide Versus Cinacalcet for Secondary Hyperparathyroidism in Hemodialysis Patients: A Multicentre Comparison with 24 Months of Follow-Up"],"prefix":"10.3390","volume":"15","author":[{"given":"Hakk\u0131","family":"\u00d6zt\u00fcrk","sequence":"first","affiliation":[{"name":"Afyonkarahisar Provincial Health Services Directorate, Afyonkarahisar 03200, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"\u00c7i\u011fdem","family":"Ikhlef","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0834-900X","authenticated-orcid":false,"given":"Berrak It\u0131r","family":"Ayl\u0131","sequence":"additional","affiliation":[{"name":"Faculty of Life Sciences, University of Westminster, London W1B 2HW, UK"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2123-5207","authenticated-orcid":false,"given":"Veysel Baran","family":"Tomar","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Gazi University, Ankara 06570, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9588-4803","authenticated-orcid":false,"given":"Bartu","family":"Ediz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kartal Dr L\u00fctf\u00fc K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Ebru G\u00f6k","family":"O\u011fuz","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Elif","family":"Ar\u0131 Bak\u0131r","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kartal Dr L\u00fctf\u00fc K\u0131rdar City Hospital, Istanbul 34865, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"given":"Galip","family":"G\u00fcz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Faculty of Medicine, Gazi University, Ankara 06570, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Mehmet Deniz","family":"Ayl\u0131","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Ankara Etlik City Hospital, Ankara 06170, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"(2024). Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_2","unstructured":"GBD 2023 Chronic Kidney Disease Collaborators (2025). Global, regional, and national burden of chronic kidney disease in adults, 1990\u20132023, and its attributable risk factors: A systematic analysis for the Global Burden of Disease Study 2023. Lancet, 406, 2461\u20132482."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfq656","article-title":"A population-based survey of Chronic REnal Disease In Turkey\u2014The CREDIT study","volume":"26","author":"Arinsoy","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","unstructured":"(2025). GBD 2023 Kidney Failure with Replacement Therapy Collaborators. Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990\u20132023: A systematic analysis for the Global Burden of Disease Study 2023. Lancet Glob. Health, 13, e1378\u2013e1395."},{"key":"ref_5","unstructured":"Seyahi, N., Ko\u00e7yi\u011fit, \u0130., and Eren, N. (2025). T\u00fcrkiye\u2019de Nefroloji, Diyaliz ve Transplantasyon Registry 2024, Turkish Society of Nephrology."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/1744-9987.70118","article-title":"Predicting the Future Burden of Renal Replacement Therapy in T\u00fcrkiye Using National Registry Data and Comparative Modeling Approaches","volume":"30","year":"2026","journal-title":"Ther. Apher. Dial."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liu, J., Fang, Y., Zhou, S., Liu, X., and Li, Z. (2024). Estimating the global prevalence of secondary hyperparathyroidism in patients with chronic kidney disease. Front. Endocrinol., 15.","DOI":"10.3389\/fendo.2024.1400891"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1016\/j.ekir.2020.09.010","article-title":"A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism (the DUET Trial)","volume":"5","author":"Itano","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"(2017). Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int. Suppl., 7, 1\u201359.","DOI":"10.1016\/j.kisu.2017.04.001"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/1744-9987.12058","article-title":"Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder","volume":"17","author":"Fukagawa","year":"2013","journal-title":"Ther. Apher. Dial."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Geng, X., Shi, E., Wang, S., and Song, Y. (2020). A comparative analysis of the efficacy and safety of paricalcitol versus other vitamin D receptor activators in patients undergoing hemodialysis: A systematic review and meta-analysis of 15 randomized controlled trials. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233705"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.clinme.2024.100238","article-title":"Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy","volume":"24","author":"Tsai","year":"2024","journal-title":"Clin. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.ajkd.2020.02.439","article-title":"Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis","volume":"76","author":"Palmer","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.19468","article-title":"Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism: A Randomized Clinical Trial","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis with Secondary Hyperparathyroidism: Two Randomized Clinical Trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/ndt\/gfz039","article-title":"One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism","volume":"35","author":"Bushinsky","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Wojtowicz, D., Laham, G., Forrester, M., del Valle, E., Pe\u00f1alba, A., Filannino, G., Sammartino, A., Mengarelli, C., Rosa-Diez, G., and Negri, A.L. (2024). Real world evaluation of etelcalcetide in the treatment of secondary hyperparathyroidism in hemodialysis patients in Argentina. Ther. Apher. Dial.","DOI":"10.1111\/1744-9987.14230"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/1744-9987.14125","article-title":"Calcimimetics treatment strategy for serum calcium and phosphate management in patients with secondary hyperparathyroidism undergoing dialysis: A systematic review and meta-analysis of randomized studies","volume":"28","author":"Nakai","year":"2024","journal-title":"Ther. Apher. Dial."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and Practical Use of Calcimimetics in Dialysis Patients with Secondary Hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6656\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T12:49:10Z","timestamp":1787921350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":20,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176656"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176656","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}